Philip Morris International (PMI) has submitted premarket tobacco product applications (PMTAs) and modified risk tobacco product applications (MRTPAs) to the US Food and Drug Administration (FDA) for its Iqos Iluma heated tobacco products (HTPs).
As previously announced during the presentation of its financial results last week, the company was expected to file the applications by the end of October.
They are strong applications backed by international evidence of how Iqos Iluma products can lead more adults to stop smoking, said Stacey Kennedy, president of Americas Region and CEO of PMI US. She urged the FDA to prioritise them for review.